
Markus Grompe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5562015/publications.pdf Version: 2024-02-01



MADKUS COMOR

#	Article	IF	CITATIONS
1	Development of a Beta Cell-Specific Expression Control Element for Recombinant Adeno-Associated Virus. Human Gene Therapy, 2022, 33, 789-800.	2.7	2
2	Induced Liver Regeneration Enhances CRISPR/Cas9-Mediated Gene Repair in Tyrosinemia Type 1. Human Gene Therapy, 2021, 32, 294-301.	2.7	11
3	MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia. Cell Stem Cell, 2021, 28, 33-47.e8.	11.1	31
4	Inhibition of TGFβ1 and TGFβ3 promotes hematopoiesis in Fanconi anemia. Experimental Hematology, 2021, 93, 70-84.e4.	0.4	8
5	Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice. Molecular Therapy, 2021, 29, 680-690.	8.2	61
6	Proliferative polyploid cells give rise to tumors via ploidy reduction. Nature Communications, 2021, 12, 646.	12.8	51
7	Therapeutic liver repopulation by transient acetaminophen selection of gene-modified hepatocytes. Science Translational Medicine, 2021, 13, .	12.4	16
8	Dynamic Transcriptional and Epigenetic Changes Drive Cellular Plasticity in the Liver. Hepatology, 2021, 74, 444-457.	7.3	20
9	AAV integration in human hepatocytes. Molecular Therapy, 2021, 29, 2898-2909.	8.2	64
10	In vitro expansion of cirrhosis derived liver epithelial cells with defined small molecules. Stem Cell Research, 2021, 56, 102523.	0.7	5
11	Metformin for Treatment of Cytopenias in Children and Young Adults with Fanconi Anemia. Blood, 2021, 138, 1102-1102.	1.4	1
12	Generation of functional ciliated cholangiocytes from human pluripotent stem cells. Nature Communications, 2021, 12, 6504.	12.8	15
13	Cancer stem cells: advances in biology and clinical translation—a Keystone Symposia report. Annals of the New York Academy of Sciences, 2021, 1506, 142-163.	3.8	8
14	AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria. Molecular Therapy - Methods and Clinical Development, 2020, 17, 234-245.	4.1	58
15	InÂVivo Lineage Tracing of Polyploid Hepatocytes Reveals Extensive Proliferation during Liver Regeneration. Cell Stem Cell, 2020, 26, 34-47.e3.	11.1	129
16	Insights From Liverâ€Humanized Mice on Cholesterol Lipoprotein Metabolism and LXRâ€Agonist Pharmacodynamics in Humans. Hepatology, 2020, 72, 656-670.	7.3	23
17	Efficient inÂvivo editing of OTC-deficient patient-derived primary human hepatocytes. JHEP Reports, 2020, 2, 100065.	4.9	18
18	Endoplasmic Reticulum Stress-Induced Upregulation of STARD1 Promotes Acetaminophen-Induced Acute Liver Failure. Gastroenterology, 2019, 157, 552-568.	1.3	85

#	Article	IF	CITATIONS
19	Diabetes relief in mice by glucose-sensing insulin-secreting human α-cells. Nature, 2019, 567, 43-48.	27.8	188
20	Loss of Oxidation Resistance 1, OXR1, Is Associated with an Autosomal-Recessive Neurological Disease with Cerebellar Atrophy and Lysosomal Dysfunction. American Journal of Human Genetics, 2019, 105, 1237-1253.	6.2	34
21	Combination therapy with atorvastatin and celecoxib delays tumor formation in a Fanconi anemia mouse model. Pediatric Blood and Cancer, 2019, 66, e27460.	1.5	6
22	Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors. JCI Insight, 2019, 4, .	5.0	64
23	Replication Stress Response and CDKN1A Engagement Constrain Fetal Hematopoietic Stem Cell Pool Size in Fanconi Anemia. Blood, 2019, 134, 107-107.	1.4	0
24	Long-Term Correction of Diabetes in Mice by InÂVivo Reprogramming of Pancreatic Ducts. Molecular Therapy, 2018, 26, 1327-1342.	8.2	25
25	Bioengineered AAV Capsids with Combined High Human Liver Transduction InÂVivo and Unique Humoral Seroreactivity. Molecular Therapy, 2018, 26, 289-303.	8.2	130
26	Monitoring liver damage using hepatocyte-specific methylation markers in cell-free circulating DNA. JCI Insight, 2018, 3, .	5.0	94
27	Inflammatory Cytokine TNFα Promotes the Long-Term Expansion of Primary Hepatocytes in 3D Culture. Cell, 2018, 175, 1607-1619.e15.	28.9	211
28	Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nature Communications, 2018, 9, 5068.	12.8	584
29	A Drug Screen using Human iPSC-Derived Hepatocyte-like Cells Reveals Cardiac Glycosides as a Potential Treatment for Hypercholesterolemia. Cell Stem Cell, 2017, 20, 478-489.e5.	11.1	92
30	Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genetics in Medicine, 2017, 19, 1380-1395.	2.4	152
31	Glycoprotein 2 is a specific cell surface marker of human pancreatic progenitors. Nature Communications, 2017, 8, 331.	12.8	115
32	Fah Knockout Animals as Models for Therapeutic Liver Repopulation. Advances in Experimental Medicine and Biology, 2017, 959, 215-230.	1.6	26
33	Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability. Nature Communications, 2017, 8, 1323.	12.8	53
34	Adult Mouse Liver Contains Two Distinct Populations of Cholangiocytes. Stem Cell Reports, 2017, 9, 478-489.	4.8	68
35	Successful Engraftment of Human Hepatocytes in uPA-SCID and FRG® KO Mice. Methods in Molecular Biology, 2017, 1506, 117-130.	0.9	17
36	Chronic Phenotype Characterization of a Large-Animal Model of Hereditary Tyrosinemia Type 1. American Journal of Pathology, 2017, 187, 33-41.	3.8	16

#	Article	IF	CITATIONS
37	Reprogramming human gallbladder cells into insulin-producing β-like cells. PLoS ONE, 2017, 12, e0181812.	2.5	35
38	Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice. Blood, 2016, 128, 2774-2784.	1.4	60
39	Efficient generation of pancreatic β-like cells from the mouse gallbladder. Stem Cell Research, 2016, 17, 587-596.	0.7	13
40	Age-Dependent Pancreatic Gene Regulation Reveals Mechanisms Governing Human β Cell Function. Cell Metabolism, 2016, 23, 909-920.	16.2	205
41	Single-Cell Mass Cytometry Analysis of the Human Endocrine Pancreas. Cell Metabolism, 2016, 24, 616-626.	16.2	126
42	Silent Tyrosinemia Type I Without Elevated Tyrosine or Succinylacetone Associated with Liver Cirrhosis and Hepatocellular Carcinoma. Human Mutation, 2016, 37, 1097-1105.	2.5	21
43	Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1. Science Translational Medicine, 2016, 8, 349ra99.	12.4	56
44	A universal system to select gene-modified hepatocytes in vivo. Science Translational Medicine, 2016, 8, 342ra79.	12.4	38
45	Human islets contain four distinct subtypes of \hat{I}^2 cells. Nature Communications, 2016, 7, 11756.	12.8	291
46	TGF-β Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in Fanconi Anemia. Cell Stem Cell, 2016, 18, 668-681.	11.1	125
47	Stem cells versus plasticity in liver and pancreas regeneration. Nature Cell Biology, 2016, 18, 238-245.	10.3	152
48	Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E1826-34.	7.1	492
49	The Sirt1 activator SRT3025 expands hematopoietic stem and progenitor cells and improves hematopoiesis in Fanconi anemia mice. Stem Cell Research, 2015, 15, 130-140.	0.7	21
50	Fibroblast Growth Factor Signaling Controls Liver Size in Mice With Humanized Livers. Gastroenterology, 2015, 149, 728-740.e15.	1.3	93
51	Oxymetholone Therapy of Fanconi Anemia Suppresses Osteopontin Transcription and Induces Hematopoietic Stem Cell Cycling. Stem Cell Reports, 2015, 4, 90-102.	4.8	26
52	Directed differentiation of cholangiocytes from human pluripotent stem cells. Nature Biotechnology, 2015, 33, 853-861.	17.5	254
53	Adeno-associated virus finds its disease. Nature Genetics, 2015, 47, 1104-1105.	21.4	36
54	Novel surface markers directed against adult human gallbladder. Stem Cell Research, 2015, 15, 172-181.	0.7	6

#	Article	IF	CITATIONS
55	Adult Liver Stem Cells. , 2014, , 309-327.		1
56	Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nature Biotechnology, 2014, 32, 551-553.	17.5	823
57	Pharmacologic inhibition of Lâ€tyrosine degradation ameliorates cerebral dopamine deficiency in murine phenylketonuria (PKU). Journal of Inherited Metabolic Disease, 2014, 37, 735-743.	3.6	38
58	Evaluation of resveratrol and <i>N</i> â€ecetylcysteine for cancer chemoprevention in a Fanconi anemia murine model. Pediatric Blood and Cancer, 2014, 61, 740-742.	1.5	13
59	Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature, 2014, 506, 382-386.	27.8	376
60	Extensive double humanization of both liver and hematopoiesis in FRGN mice. Stem Cell Research, 2014, 13, 404-412.	0.7	123
61	Bipotential Adult Liver Progenitors Are Derived from Chronically Injured Mature Hepatocytes. Cell Stem Cell, 2014, 15, 605-618.	11.1	427
62	The organoid-initiating cells in mouse pancreas and liver are phenotypically and functionally similar. Stem Cell Research, 2014, 13, 275-283.	0.7	71
63	Liver Stem Cells, Where Art Thou?. Cell Stem Cell, 2014, 15, 257-258.	11.1	73
64	Clonal tracing of Sox9 ⁺ liver progenitors in mouse oval cell injury. Hepatology, 2014, 60, 278-289.	7.3	190
65	Fumarylacetoacetate hydrolase deficient pigs are a novel large animal model of metabolic liver disease. Stem Cell Research, 2014, 13, 144-153.	0.7	59
66	Human pancreatic cancer fusion 2 (HPC2) 1â€83: A novel monoclonal antibody to screen for pancreatic ductal dysplasia. Cancer Cytopathology, 2013, 121, 37-46.	2.4	3
67	Response to "Can â€`humanized' mice improve drug development in the 21st century?― Trends in Pharmacological Sciences, 2013, 34, 425.	8.7	5
68	Generation of islet-like cells from mouse gall bladder by direct ex vivo reprogramming. Stem Cell Research, 2013, 11, 503-515.	0.7	44
69	Assessing the potential of induced liver regeneration. Nature Medicine, 2013, 19, 1096-1097.	30.7	11
70	Anthracyclines Induce DNA Damage Response-Mediated Protection against Severe Sepsis. Immunity, 2013, 39, 874-884.	14.3	131
71	New potential cell source for hepatocyte transplantation: Discarded livers from metabolic disease liver transplants. Stem Cell Research, 2013, 11, 563-573.	0.7	53
72	Mice With Human Livers. Gastroenterology, 2013, 145, 1209-1214.	1.3	114

#	Article	IF	CITATIONS
73	Fancd2 and p21 function independently in maintaining the size of hematopoietic stem and progenitor cell pool in mice. Stem Cell Research, 2013, 11, 687-692.	0.7	11
74	p53 regulates a mitotic transcription program and determines ploidy in normal mouse liver. Hepatology, 2013, 57, 2004-2013.	7.3	83
75	In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature, 2013, 494, 247-250.	27.8	1,239
76	Adult Liver Stem Cells. , 2013, , 873-887.		0
77	A Therapy for Liver Failure Found in the JNK Yard. Cell, 2013, 153, 283-284.	28.9	5
78	Epigenomic plasticity enables human pancreatic Î $_{\pm}$ to Î 2 cell reprogramming. Journal of Clinical Investigation, 2013, 123, 1275-1284.	8.2	365
79	Mice with Chimeric Livers Are an Improved Model for Human Lipoprotein Metabolism. PLoS ONE, 2013, 8, e78550.	2.5	45
80	AAV Vectors Containing rDNA Homology Display Increased Chromosomal Integration and Transgene Persistence. Molecular Therapy, 2012, 20, 1902-1911.	8.2	36
81	In Vivo Selection of Transplanted Hepatocytes by Pharmacological Inhibition of Fumarylacetoacetate Hydrolase in Wild-type Mice. Molecular Therapy, 2012, 20, 1981-1987.	8.2	15
82	Ribosomal DNA Integrating rAAV-rDNA Vectors Allow for Stable Transgene Expression. Molecular Therapy, 2012, 20, 1912-1923.	8.2	27
83	Intra-hematopoietic cell fusion as a source of somatic variation in the hematopoietic system. Journal of Cell Science, 2012, 125, 2837-43.	2.0	20
84	Frequent Aneuploidy Among Normal Human Hepatocytes. Gastroenterology, 2012, 142, 25-28.	1.3	175
85	AAV-Mediated Gene Targeting Is Significantly Enhanced by Transient Inhibition of Nonhomologous End Joining or the Proteasome <i>In Vivo</i> . Human Gene Therapy, 2012, 23, 658-665.	2.7	30
86	Tissue Stem Cells: New Tools and Functional Diversity. Cell Stem Cell, 2012, 10, 685-689.	11.1	51
87	Bone Marrow Failure in Fanconi Anemia Is Triggered by an Exacerbated p53/p21 DNA Damage Response that Impairs Hematopoietic Stem and Progenitor Cells. Cell Stem Cell, 2012, 11, 36-49.	11.1	262
88	The novel monoclonal antibody HPC2 and N-cadherin distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma. Human Pathology, 2012, 43, 1583-1589.	2.0	18
89	Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. Journal of Clinical Investigation, 2012, 122, 3618-3628.	8.2	200
90	Aneuploidy as a mechanism for stress-induced liver adaptation. Journal of Clinical Investigation, 2012, 122, 3307-3315.	8.2	147

#	Article	IF	CITATIONS
91	Intra-hematopoietic cell fusion as a source of somatic variation in the hematopoietic system. Development (Cambridge), 2012, 139, e1707-e1707.	2.5	0
92	Isolation of mouse pancreatic alpha, beta, duct and acinar populations with cell surface markers. Molecular and Cellular Endocrinology, 2011, 339, 144-150.	3.2	44
93	Transcriptomes of the major human pancreatic cell types. Diabetologia, 2011, 54, 2832-44.	6.3	194
94	Fanconi anemiaâ€like presentation in an infant with constitutional deletion of 21q including the <i>RUNX1</i> gene. American Journal of Medical Genetics, Part A, 2011, 155, 1673-1679.	1.2	17
95	Efficient production of <i>Fah</i> -null heterozygote pigs by chimeric adeno-associated virus-mediated gene knockout and somatic cell nuclear transfer. Hepatology, 2011, 54, 1351-1359.	7.3	69
96	Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. Journal of Experimental Medicine, 2011, 208, 1963-1976.	8.5	183
97	Foxl1-Cre-marked adult hepatic progenitors have clonogenic and bilineage differentiation potential. Genes and Development, 2011, 25, 1185-1192.	5.9	138
98	Prospective isolation of a bipotential clonogenic liver progenitor cell in adult mice. Genes and Development, 2011, 25, 1193-1203.	5.9	209
99	Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. Journal of Cell Biology, 2011, 194, i11-i11.	5.2	0
100	Fancd2 â~'/â^' mice have hematopoietic defects that can be partially corrected by resveratrol. Blood, 2010, 116, 5140-5148.	1.4	83
101	Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology, 2010, 51, 1200-1208.	7.3	121
102	The ploidy conveyor of mature hepatocytes as a source of genetic variation. Nature, 2010, 467, 707-710.	27.8	432
103	Non-Invasive Stem Cell Therapy in a Rat Model for Retinal Degeneration and Vascular Pathology. PLoS ONE, 2010, 5, e9200.	2.5	129
104	Deficiencies in the Fanconi Anemia DNA Damage Response Pathway Increase Sensitivity to HPV-Associated Head and Neck Cancer. Cancer Research, 2010, 70, 9959-9968.	0.9	81
105	Therapeutic Liver Reconstitution With Murine Cells Isolated Long After Death. Gastroenterology, 2010, 139, 1019-1029.	1.3	29
106	Chimeric Mice with Humanized Liver: Tools for the Study of Drug Metabolism, Excretion, and Toxicity. Methods in Molecular Biology, 2010, 640, 491-509.	0.9	133
107	Chromosomal Integration of Adenoviral Vector DNA <i>In Vivo</i> . Journal of Virology, 2010, 84, 9987-9994.	3.4	77
108	Adult Liver Stem Cells. , 2009, , 285-298.		1

Adult Liver Stem Cells. , 2009, , 285-298. 108

#	Article	IF	CITATIONS
109	Validation of Fanconi anemia complementation Group A assignment using molecular analysis. Genetics in Medicine, 2009, 11, 183-192.	2.4	13
110	Ploidy Reductions in Murine Fusion-Derived Hepatocytes. PLoS Genetics, 2009, 5, e1000385.	3.5	91
111	Embryonic Lethality after Combined Inactivation of <i>Fancd2</i> and <i>Mlh1</i> in Mice. Cancer Research, 2009, 69, 9431-9438.	0.9	9
112	Generation of Monoclonal Antibodies Specific for Cell Surface Molecules Expressed on Early Mouse Endoderm. Stem Cells, 2009, 27, 2103-2113.	3.2	38
113	CDX2 in the formation of the trophectoderm lineage in primate embryos. Developmental Biology, 2009, 335, 179-187.	2.0	35
114	Stem Cells and Liver Regeneration. Gastroenterology, 2009, 137, 466-481.	1.3	469
115	Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development. Hepatology, 2008, 48, 487-496.	7.3	36
116	Surface markers for the murine oval cell response. Hepatology, 2008, 48, 1282-1291.	7.3	85
117	CXCR4 induction in hematopoietic progenitor cells from Fancaâ^'/â^', -câ^'/â^', and -d2â^'/â^' mice. Experimental Hematology, 2008, 36, 273-282.	0.4	12
118	Loss of p21 Permits Carcinogenesis from Chronically Damaged Liver and Kidney Epithelial Cells despite Unchecked Apoptosis. Cancer Cell, 2008, 14, 59-67.	16.8	60
119	Signaling networks in hepatic oval cell activation. Stem Cell Research, 2008, 1, 90-102.	0.7	49
120	Isolation of major pancreatic cell types and long-term culture-initiating cells using novel human surface markers. Stem Cell Research, 2008, 1, 183-194.	0.7	110
121	ERCC1 is required for FANCD2 focus formation. Molecular Genetics and Metabolism, 2008, 95, 66-73.	1.1	18
122	Generation and Regeneration of Cells of the Liver and Pancreas. Science, 2008, 322, 1490-1494.	12.6	530
123	Tempol Protects against Oxidative Damage and Delays Epithelial Tumor Onset in Fanconi Anemia Mice. Cancer Research, 2008, 68, 1601-1608.	0.9	66
124	Bone Marrow-Derived Hepatocytes. Novartis Foundation Symposium, 2008, , 20-34.	1.1	24
125	Slow-onset inhibition of fumarylacetoacetate hydrolase by phosphinate mimics of the tetrahedral intermediate: kinetics, crystal structure and pharmacokinetics. Biochemical Journal, 2007, 402, 251-260.	3.7	16
126	The Fanconi Family Adds a Fraternal Twin. Developmental Cell, 2007, 12, 661-662.	7.0	30

#	Article	IF	CITATIONS
127	Hypomorphic Mutations in the Gene Encoding a Key Fanconi Anemia Protein, FANCD2, Sustain a Significant Group of FA-D2 Patients with Severe Phenotype. American Journal of Human Genetics, 2007, 80, 895-910.	6.2	115
128	Robust expansion of human hepatocytes in Fahâ^'/â^'/Rag2â^'/â^'/Il2rgâ^'/â^' mice. Nature Biotechnology, 2007, 25, 903-910.	17.5	729
129	Bone marrow-derived cells fuse with normal and transformed intestinal stem cells. Proceedings of the United States of America, 2006, 103, 6321-6325.	7.1	250
130	Sustained Phosphorylation of Bid Is a Marker for Resistance to Fas-Induced Apoptosis During Chronic Liver Diseases. Gastroenterology, 2006, 130, 104-119.	1.3	31
131	Natural gene therapy in monozygotic twins with Fanconi anemia. Blood, 2006, 107, 3084-3090.	1.4	76
132	Principles of therapeutic liver repopulation. Journal of Inherited Metabolic Disease, 2006, 29, 421-425.	3.6	52
133	Myeloid lineage progenitors give rise to vascular endothelium. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 13156-13161.	7.1	184
134	In Vivo Genetic Selection of Renal Proximal Tubules. Molecular Therapy, 2006, 13, 49-58.	8.2	58
135	Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. Journal of Clinical Investigation, 2006, 116, 3070-3082.	8.2	197
136	Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin. Blood, 2005, 105, 1003-1009.	1.4	118
137	Liver Repair by Intra- and Extrahepatic Progenitors. Stem Cell Reviews and Reports, 2005, 1, 061-064.	5.6	33
138	Embryonic stem cells without embryos?. Nature Biotechnology, 2005, 23, 1496-1497.	17.5	5
139	Large-Scale Molecular Characterization of Adeno-Associated Virus Vector Integration in Mouse Liver. Journal of Virology, 2005, 79, 3606-3614.	3.4	164
140	In Vivo Correction of Murine Hereditary Tyrosinemia Type I by ϕC31 Integrase-Mediated Gene Delivery. Molecular Therapy, 2005, 11, 399-408.	8.2	128
141	Low Therapeutic Threshold for Hepatocyte Replacement in Murine Phenylketonuria. Molecular Therapy, 2005, 12, 337-344.	8.2	53
142	Fancd2 functions in a double strand break repair pathway that is distinct from non-homologous end joining. Human Molecular Genetics, 2005, 14, 3027-3033.	2.9	54
143	The Origin of Hepatocytes. Gastroenterology, 2005, 128, 2158-2160.	1.3	22
144	Heterozygosity for p53 (Trp53+/-) accelerates epithelial tumor formation in fanconi anemia complementation group D2 (Fancd2) knockout mice. Cancer Research, 2005, 65, 85-91.	0.9	45

#	Article	IF	CITATIONS
145	Bone marrow-derived hepatocytes. Novartis Foundation Symposium, 2005, 265, 20-7; discussion 28-34, 92-7.	1.1	7
146	Adult Liver Stem Cells. , 2004, , 483-495.		0
147	Repair Kinetics of Genomic Interstrand DNA Cross-Links: Evidence for DNA Double-Strand Break-Dependent Activation of the Fanconi Anemia/BRCA Pathway. Molecular and Cellular Biology, 2004, 24, 123-134.	2.3	215
148	Delineating the Hepatocyte's Hematopoietic Fusion Partner. Cell Cycle, 2004, 3, 1489-1491.	2.6	16
149	Liver-Directed Adenoviral Gene Transfer in Murine Succinate Semialdehyde Dehydrogenase Deficiency. Molecular Therapy, 2004, 9, 527-539.	8.2	25
150	Renal proximal tubular cells acquire resistance to cell death stimuli in mice with hereditary tyrosinemia type 1. Kidney International, 2004, 66, 990-1000.	5.2	7
151	Myelomonocytic cells are sufficient for therapeutic cell fusion in liver. Nature Medicine, 2004, 10, 744-748.	30.7	409
152	The importance of knowing your identity: Sources of confusion in stem cell biology. Hepatology, 2004, 39, 35-37.	7.3	16
153	Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death. Hepatology, 2004, 39, 433-443.	7.3	61
154	Interstrand crosslink-induced radials form between non-homologous chromosomes, but are absent in sex chromosomes. DNA Repair, 2004, 3, 535-542.	2.8	31
155	Embryonic versus adult stem cell pluripotency: in liver only fusion matters. Journal of Assisted Reproduction and Genetics, 2003, 20, 393-394.	2.5	7
156	Pharmacologic or genetic ablation of maleylacetoacetate isomerase increases levels of toxic tyrosine catabolites in rodents. Biochemical Pharmacology, 2003, 66, 2029-2038.	4.4	30
157	Mutational spectrum of the succinate semialdehyde dehydrogenase (ALDH5A1) gene and functional analysis of 27 novel disease-causing mutations in patients with SSADH deficiency. Human Mutation, 2003, 22, 442-450.	2.5	117
158	Murine succinate semialdehyde dehydrogenase deficiency. Annals of Neurology, 2003, 54, S81-S90.	5.3	48
159	Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature, 2003, 422, 897-901.	27.8	1,537
160	FANCL, as in ligase. Nature Genetics, 2003, 35, 113-114.	21.4	7
161	AAV serotype 2 vectors preferentially integrate into active genes in mice. Nature Genetics, 2003, 34, 297-302.	21.4	359
162	The Fanconi anaemia/BRCA pathway. Nature Reviews Cancer, 2003, 3, 23-34.	28.4	764

#	Article	IF	CITATIONS
163	Pancreatic–hepatic switches in vivo. Mechanisms of Development, 2003, 120, 99-106.	1.7	51
164	The Multiple Sulfatase Deficiency Gene Encodes an Essential and Limiting Factor for the Activity of Sulfatases. Cell, 2003, 113, 445-456.	28.9	321
165	Epithelial cancer in Fanconi anemia complementation group D2 (<i>Fancd2</i>) knockout mice. Genes and Development, 2003, 17, 2021-2035.	5.9	240
166	The origin and liver repopulating capacity of murine oval cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11881-11888.	7.1	399
167	Helper-independent and AAV-ITR-independent chromosomal integration of double-stranded linear DNA vectors in mice. Molecular Therapy, 2003, 7, 101-111.	8.2	48
168	The Role of Bone Marrow Stem Cells in Liver Regeneration. Seminars in Liver Disease, 2003, 23, 363-372.	3.6	94
169	Reply to "Involvement of oxidative stress in Fanconi's anaemia: from phenotype to FA protein functions― Nature Reviews Cancer, 2003, 3, 78-78.	28.4	0
170	In Vivo Correction of Murine Tyrosinemia Type I by DNA-Mediated Transposition. Molecular Therapy, 2002, 6, 759-769.	8.2	137
171	Biallelic Inactivation of <i>BRCA2</i> in Fanconi Anemia. Science, 2002, 297, 606-609.	12.6	1,072
172	Attenuation of the formation of DNA-repair foci containing RAD51 in Fanconi anaemia. Carcinogenesis, 2002, 23, 1121-1126.	2.8	81
173	Gene Therapy and Pediatric Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2002, 35, S51-S54.	1.8	5
174	BRCA1 interacts directly with the Fanconi anemia protein FANCA. Human Molecular Genetics, 2002, 11, 2591-2597.	2.9	101
175	Therapeutic Intervention in Mice Deficient for Succinate Semialdehyde Dehydrogenase (γ-Hydroxybutyric Aciduria). Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 180-187.	2.5	81
176	Maleylacetoacetate Isomerase (MAAI/GSTZ)-Deficient Mice Reveal a Glutathione-Dependent Nonenzymatic Bypass in Tyrosine Catabolism. Molecular and Cellular Biology, 2002, 22, 4943-4951.	2.3	89
177	S-phase–specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood, 2002, 100, 2414-2420.	1.4	426
178	Gene therapy of Fanconi anemia: preclinical efficacy using lentiviral vectors. Blood, 2002, 100, 2732-2736.	1.4	82
179	Kinetics of Liver Repopulation after Bone Marrow Transplantation. American Journal of Pathology, 2002, 161, 565-574.	3.8	233
180	Mutations in PHF6 are associated with Börjeson–Forssman–Lehmann syndrome. Nature Genetics, 2002, 32, 661-665.	21.4	192

#	Article	IF	CITATIONS
181	Sandgren EP, Palmiter RD, Heckel JL, Daugherty CC, Brinster RL, Degen JL. Complete hepatic regeneration after somatic deletion of an albumin–plasminogen activator transgene [Cell 1991;66:245–256]. Journal of Hepatology, 2002, 37, 422-424.	3.7	9
182	Adult versus Embryonic Stem Cells: It's Still a Tie. Molecular Therapy, 2002, 6, 303-305.	8.2	29
183	Fanconi anemia group A and C double-mutant mice. Experimental Hematology, 2002, 30, 679-688.	0.4	58
184	In vivo administration of interferon \hat{I}^3 does not cause marrow aplasia in mice with a targeted disruption of FANCC. Experimental Hematology, 2002, 30, 1257-1262.	0.4	7
185	SV40 large T-antigen disturbs the formation of nuclear DNA-repair foci containing MRE11. Oncogene, 2002, 21, 4873-4878.	5.9	57
186	FANCD2: A branch-point in DNA damage response?. Nature Medicine, 2002, 8, 555-556.	30.7	11
187	Transition of Stem Cells to Therapeutically Functional Tissueâ€Specific Cells. Annals of the New York Academy of Sciences, 2002, 961, 305-306.	3.8	6
188	The 4N Cell Cycle Delay in Fanconi Anemia Reflects Growth Arrest in Late S Phase. Molecular Genetics and Metabolism, 2001, 74, 403-412.	1.1	68
189	Liver Repopulation and Correction of Metabolic Liver Disease by Transplanted Adult Mouse Pancreatic Cells. American Journal of Pathology, 2001, 158, 571-579.	3.8	114
190	Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase. Nature Genetics, 2001, 29, 212-216.	21.4	149
191	Positional Cloning of a Novel Fanconi Anemia Gene, FANCD2. Molecular Cell, 2001, 7, 241-248.	9.7	370
192	Interaction of the Fanconi Anemia Proteins and BRCA1 in a Common Pathway. Molecular Cell, 2001, 7, 249-262.	9.7	1,125
193	Liver repopulation for the treatment of metabolic diseases. Journal of Inherited Metabolic Disease, 2001, 24, 231-244.	3.6	44
194	Mouse liver goes human: A new tool in experimental hepatology. Hepatology, 2001, 33, 1005-1006.	7.3	11
195	Functional analysis of patient-derived mutations in the Fanconi anemia gene, FANCG/XRCC9. Experimental Hematology, 2001, 29, 842-849.	0.4	20
196	Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells. Experimental Hematology, 2001, 29, 1448-1455.	0.4	37
197	Preclinical Protocol for in Vivo Selection of Hematopoietic Stem Cells Corrected by Gene Therapy in Fanconi Anemia Group C. Molecular Therapy, 2001, 3, 14-23.	8.2	37
198	Fanconi anemia and DNA repair. Human Molecular Genetics, 2001, 10, 2253-2259.	2.9	159

#	Article	IF	CITATIONS
199	Mechanistic Inferences from the Crystal Structure of Fumarylacetoacetate Hydrolase with a Bound Phosphorus-based Inhibitor. Journal of Biological Chemistry, 2001, 276, 15284-15291.	3.4	54
200	The Pathophysiology and Treatment of Hereditary Tyrosinemia Type 1. Seminars in Liver Disease, 2001, 21, 563-572.	3.6	155
201	Loss of p27Kip1 enhances the transplantation efficiency of hepatocytes transferred into diseased livers. Journal of Clinical Investigation, 2001, 108, 383-390.	8.2	45
202	Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nature Medicine, 2000, 6, 1229-1234.	30.7	2,255
203	Phenotypic correction of Fanconi anemia group C knockout mice. Blood, 2000, 95, 700-704.	1.4	54
204	DNA Replication Is Required To Elicit Cellular Responses to Psoralen-Induced DNA Interstrand Cross-Links. Molecular and Cellular Biology, 2000, 20, 8283-8289.	2.3	183
205	Localization of the Fanconi Anemia Complementation Group D Gene to a 200-kb Region on Chromosome 3p25.3. American Journal of Human Genetics, 2000, 66, 1540-1551.	6.2	30
206	Proliferation, But Not Growth, Blocked by Conditional Deletion of 40S Ribosomal Protein S6. Science, 2000, 288, 2045-2047.	12.6	350
207	DNA Replication Is Required To Elicit Cellular Responses to Psoralen-Induced DNA Interstrand Cross-Links. Molecular and Cellular Biology, 2000, 20, 8283-8289.	2.3	18
208	In Vivo Selection of Wild-Type Hematopoietic Stem Cells in a Murine Model of Fanconi Anemia. Blood, 1999, 94, 2151-2158.	1.4	52
209	Principles of Therapeutic Liver Repopulation. Seminars in Liver Disease, 1999, 19, 7-14.	3.6	84
210	Embryonic stem cells can be used to construct hybrid cell lines containing a single, selectable murine chromosome. Mammalian Genome, 1999, 10, 381-384.	2.2	2
211	Tumor necrosis factor-? and CD95 ligation suppress erythropoiesis in fanconi anemia C gene knockout mice. , 1999, 179, 79-86.		58
212	Identification of the mutation in the alkaptonuria mouse model. Human Mutation, 1999, 13, 171-171.	2.5	50
213	The Repopulation Potential of Hepatocyte Populations Differing in Size and Prior Mitotic Expansion. American Journal of Pathology, 1999, 155, 2135-2143.	3.8	176
214	Gene Structure, Chromosomal Location, and Expression Pattern of Maleylacetoacetate Isomerase. Genomics, 1999, 58, 263-269.	2.9	41
215	<i>Ex Vivo</i> Hepatic Gene Therapy of a Mouse Model of Hereditary Tyrosinemia Type I. Human Gene Therapy, 1998, 9, 295-304.	2.7	68
216	Chemical Cleavage of Heteroduplex DNA to Identify Mutations. Current Protocols in Human Genetics, 1998, 17, Unit 7.6.	3.5	0

#	Article	IF	CITATIONS
217	Subtyping Analysis of Fanconi Anemia by Immunoblotting and Retroviral Gene Transfer. Molecular Medicine, 1998, 4, 468-479.	4.4	55
218	DNA Cross-Linker–Induced G2/M Arrest in Group C Fanconi Anemia Lymphoblasts Reflects Normal Checkpoint Function. Blood, 1998, 91, 275-287.	1.4	71
219	DNA Cross-Linker–Induced G2/M Arrest in Group C Fanconi Anemia Lymphoblasts Reflects Normal Checkpoint Function. Blood, 1998, 91, 275-287.	1.4	1
220	Adenovirus-Mediated Gene Therapy in a Mouse Model of Hereditary Tyrosinemia Type I. Human Gene Therapy, 1997, 8, 513-521.	2.7	69
221	Molecular Biology of Fanconi Anemia: Implications for Diagnosis and Therapy. Blood, 1997, 90, 1725-1736.	1.4	192
222	Inactivation of the Fanconi Anemia Group C Gene Augments Interferon-γ–Induced Apoptotic Responses in Hematopoietic Cells. Blood, 1997, 90, 974-985.	1.4	165
223	Inactivation of the Fanconi Anemia Group C Gene Augments Interferon-γ–Induced Apoptotic Responses in Hematopoietic Cells. Blood, 1997, 90, 974-985.	1.4	9
224	[1]Chemical mismatch cleavage. Methods in Molecular Genetics, 1996, , 3-13.	0.6	0
225	Six novel mutations in the fumarylacetoacetate hydrolase gene of patients with hereditary tyrosinemia type I. Human Mutation, 1996, 7, 367-369.	2.5	10
226	Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nature Genetics, 1996, 12, 266-273.	21.4	546
227	Rapid nonradioactive assay for the detection of the common French Canadian tyrosinemia type I mutation. Human Mutation, 1995, 5, 105-105.	2.5	10
228	Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nature Genetics, 1995, 10, 453-460.	21.4	303
229	Microcell mediated chromosome transfer maps the Fanconi anaemia group D gene to chromosome 3p. Nature Genetics, 1995, 11, 341-343.	21.4	133
230	Cloning and Characterization of a Human cDNA (INPPL1) Sharing Homology with Inositol Polyphosphate Phosphatases. Genomics, 1995, 29, 285-287.	2.9	45
231	A Single Mutation of the Fumarylacetoacetate Hydrolase Gene in French Canadians with Hereditary Tyrosinemia Type I. New England Journal of Medicine, 1994, 331, 353-357.	27.0	136
232	Fanconi anemia cells have a normal gene structure for topoisomerase I. Human Genetics, 1994, 93, 583-6.	3.8	7
233	The Ashkenazi Jewish Fanconi anemia mutation: Incidence among patients and carrier frequency in the at-risk population. Human Mutation, 1994, 3, 339-341.	2.5	39
234	Microphthalmia with linear skin defects (MLS) syndrome: Clinical, cytogenetic, and molecular characterization. American Journal of Medical Genetics Part A, 1994, 49, 229-234.	2.4	100

#	Article	IF	CITATIONS
235	Mutations of the fumarylacetoacetate hydrolase gene in four patients with tyrosinemia, type I. Human Mutation, 1993, 2, 85-93.	2.5	51
236	A common mutation in the FACC gene causes Fanconi anaemia in Ashkenazi Jews. Nature Genetics, 1993, 4, 202-205.	21.4	161
237	The rapid detection of unknown mutations in nucleic acids. Nature Genetics, 1993, 5, 111-117.	21.4	316
238	Retroviral-Mediated Gene Transfer of Human Ornithine Transcarbamylase into Primary Hepatocytes of <i>spf</i> and <i>spf-ash</i> Mice. Human Gene Therapy, 1992, 3, 35-44.	2.7	56
239	The sulfatase gene family: Cross-species PCR cloning using the MOPAC technique. Genomics, 1992, 12, 755-760.	2.9	22
240	Point mutations and polymorphisms in the human dystrophin gene identified in genomic DNA sequences amplified by multiplex PCR. Human Genetics, 1992, 89, 253-8.	3.8	52
241	Nucleotide sequence of a cDNA encoding murine fumarylacetoacetate hydrolase. Biochemical Medicine and Metabolic Biology, 1992, 48, 26-31.	0.7	14
242	A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. Nature, 1991, 349, 38-44.	27.8	1,357
243	Characterization of a murine gene expressed from the inactive X chromosome. Nature, 1991, 351, 325-329.	27.8	527
244	Molecular detection and correction of ornithine transcarbamylase deficiency. Trends in Genetics, 1990, 6, 335-339.	6.7	13
245	Scanning detection of mutations in human ornithine transcarbamoylase by chemical mismatch cleavage Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 5888-5892.	7.1	129